id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-276194-4sfc7hal	Vijayvargiya, Prakhar	In Reply–The “Perfect Cytokine Storm” of COVID-19	2020-05-29		.txt	text/plain	794	59	44	To the Editor:We read with great interest the letter by Testori regarding our Review article "Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)," 1 Testori pointed out the important association of pro-inflammatory cytokines in the pathogenesis of Coronavirus disease 2019 , which could account for the worse outcome in older individuals. Baricitinib will be tested as one of the drugs in the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT). Since the online publication of our review, the investigational RNA-dependent RNA inhibitor, remdesivir, has been granted emergency use authorization in United States Food and Drug Administration based on preliminary data obtained from the ACTT. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19	./cache/cord-276194-4sfc7hal.txt	./txt/cord-276194-4sfc7hal.txt